Related Experiment Videos
Adrenocortical carcinoma: surgical progress or status quo?
M L Kendrick1, R Lloyd, L Erickson
1Department of Surgery, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA.
Archives of Surgery (Chicago, Ill. : 1960)
|May 18, 2001
Summary
Improved imaging has enhanced outcomes for adrenocortical carcinoma (ACC) patients. Current treatment focuses on surgical resection for early stages and adjuvant therapy for advanced disease, showing better survival rates compared to historical data.
Area of Science:
- Endocrinology
- Surgical Oncology
- Adrenal Gland Neoplasms
Background:
- Adrenocortical carcinoma (ACC) outcomes have seen improvement due to advancements in imaging quality and availability.
- Despite imaging progress, operative management strategies and the use of adjuvant therapy for ACC have remained largely unchanged.
Purpose of the Study:
- To evaluate the outcomes of patients with adrenocortical carcinoma (ACC) treated with operative management.
- To identify prognostic factors influencing recurrence and survival in ACC patients.
- To assess the impact of adjuvant therapy on overall outcomes in ACC.
Main Methods:
- Retrospective review of patient data including histories, imaging, operative details, and adjuvant therapy.
- Analysis of outcomes for 58 patients undergoing primary operative management for ACC between 1980 and 1996.
- Comparison of current patient data with prior institutional experience from 1960 to 1980.
Main Results:
- A total of 58 patients (mean age 53 years) underwent primary operative management for ACC.
- 5-year survival was 37% for current patients, a significant improvement from 16% in historical comparisons.
- Factors influencing prognosis included functional tumor status, disease stage, and the use of chemotherapy in advanced stages.
Conclusions:
- Surgical resection is the primary treatment for stages I to III adrenocortical carcinoma.
- Adjuvant therapy may enhance survival for patients diagnosed with stage III or IV ACC.
- Contemporary patients present with earlier stage disease, undergo more curative resections, and exhibit improved survival rates compared to historical cohorts.